For its fourth fiscal quarter (ending December 31), Halozyme Therapeutics Inc (NASDAQ: HALO) has reported a 64% increase in E.P.S. from $0.66 a year ago to $1.08 in the current quarter. E.P.S. were $3.50 for the latest four quarters through December 31 versus $2.13 for the same period a year ago — an increase of 64%.
Recent Price Action
On 2/18/25, Halozyme Therapeutics Inc (NASDAQ: HALO) stock declined slightly by -0.7%, closing at $57.90. Moreover, above average trading volume at 125% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and has risen 1.4% during the last week.
Current PriceTarget Research Rating
Halozyme Therapeutics has a current Value Trend Rating of B (Positive). With this rating, PTR's two proprietary measures of a stock's current attractiveness are providing inconsistent signals. Halozyme Therapeutics has a very high Appreciation Score of 98 but a neutral Power Rating of 44, with the Positive Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of B. This review will be completed in the next several days.